Nationwide Fund Advisors decreased its position in shares of GlycoMimetics, Inc. (NASDAQ:GLYC) by 32.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,866 shares of the biotechnology company’s stock after selling 7,058 shares during the quarter. Nationwide Fund Advisors owned approximately 0.06% of GlycoMimetics worth $166,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Russell Investments Group Ltd. boosted its position in shares of GlycoMimetics by 172.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 31,379 shares of the biotechnology company’s stock valued at $350,000 after acquiring an additional 19,859 shares during the last quarter. TD Asset Management Inc. acquired a new position in GlycoMimetics in the second quarter valued at about $362,000. Bank of New York Mellon Corp lifted its position in GlycoMimetics by 159.4% in the second quarter. Bank of New York Mellon Corp now owns 92,911 shares of the biotechnology company’s stock valued at $1,037,000 after buying an additional 57,091 shares during the last quarter. Ameriprise Financial Inc. acquired a new position in GlycoMimetics in the second quarter valued at about $1,075,000. Finally, Columbus Circle Investors acquired a new position in GlycoMimetics in the second quarter valued at about $1,516,000. 92.47% of the stock is currently owned by hedge funds and other institutional investors.

In other GlycoMimetics news, SVP Helen M. Thackray sold 2,000 shares of the business’s stock in a transaction dated Monday, September 18th. The shares were sold at an average price of $13.00, for a total transaction of $26,000.00. Following the sale, the senior vice president now directly owns 150,615 shares in the company, valued at $1,957,995. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 43.80% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: “Nationwide Fund Advisors Sells 7,058 Shares of GlycoMimetics, Inc. (GLYC)” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/nationwide-fund-advisors-sells-7058-shares-of-glycomimetics-inc-glyc/1711124.html.

Shares of GlycoMimetics, Inc. (NASDAQ:GLYC) opened at $12.27 on Friday. GlycoMimetics, Inc. has a one year low of $3.82 and a one year high of $16.94.

GlycoMimetics (NASDAQ:GLYC) last issued its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.04. equities analysts predict that GlycoMimetics, Inc. will post -1.15 earnings per share for the current year.

GLYC has been the topic of a number of recent analyst reports. ValuEngine raised shares of GlycoMimetics from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Stifel Nicolaus reaffirmed a “buy” rating and issued a $17.00 target price (up previously from $13.00) on shares of GlycoMimetics in a research report on Friday, August 4th. BidaskClub cut shares of GlycoMimetics from a “hold” rating to a “sell” rating in a research report on Thursday, August 17th. Roth Capital initiated coverage on shares of GlycoMimetics in a research report on Monday, October 23rd. They issued a “buy” rating and a $25.00 target price on the stock. Finally, Zacks Investment Research raised shares of GlycoMimetics from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a research report on Friday, October 6th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $17.33.

About GlycoMimetics

GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.

Want to see what other hedge funds are holding GLYC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlycoMimetics, Inc. (NASDAQ:GLYC).

Institutional Ownership by Quarter for GlycoMimetics (NASDAQ:GLYC)

Receive News & Ratings for GlycoMimetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.